<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="286">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998257</url>
  </required_header>
  <id_info>
    <org_study_id>14785</org_study_id>
    <secondary_id>YA0910KR</secondary_id>
    <secondary_id>YAZ rPMS</secondary_id>
    <nct_id>NCT00998257</nct_id>
  </id_info>
  <brief_title>Regulatory Post Marketing Surveillance Study on YAZ</brief_title>
  <official_title>Regulatory Post Marketing Surveillance Study on YAZ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Post Marketing Surveillance (PMS) is to gain information about safety
      and efficacy in real practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Adverse event collection</measure>
    <time_frame>After taking YAZ for 3 cycles and 6 cycles (1 cycle is 28 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Contraception efficacy</measure>
    <time_frame>After taking YAZ for 3 cycles and 6 cycles (1 cycle is 28 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>After taking YAZ for 3 cycles and 6 cycles (1 cycle is 28 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Release of Premenstrual Dysphoric Disorder (PMDD) or acne</measure>
    <time_frame>After taking YAZ for 3 cycles and 6 cycles (1 cycle is 28 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who used YAZ just for contraception</measure>
    <time_frame>At initial visit (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who used YAZ for PMDD + contraception</measure>
    <time_frame>At initial visit (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who used YAZ for Acne + contraception</measure>
    <time_frame>At initial visit (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">770</enrollment>
  <condition>Contraception</condition>
  <condition>Premenstrual Syndrome</condition>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE20/DRSP (YAZ, BAY86-5300)</intervention_name>
    <description>Patients under daily life treatment with YAZ according to local drug information.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      n.a
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Korean female who need only contraception or contraception and management of PMDD or
        contraception  and  treatment of acne.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects

               -  requesting contraception

               -  suggesting PMDD by Physician who are also requesting contraception

               -  with acne who are also requesting contraception

          -  Age: 18 - 50 years

          -  Women who is prescribed YAZ first, during study period

        Exclusion Criteria:

          -  Women who are contraindicated based on the label of YAZ

               -  Presence or a history of venous or arterial thrombotic/ thromboembolic events
                  (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a
                  cerebrovascular accident

               -  Presence or history of prodromi of a thrombosis (e.g. transient ischaemic
                  attack, angina pectoris)

               -  History of migraine with focal neurological symptoms

               -  Diabetes mellitus with vascular involvement

               -  The presence of a severe or multiple risk factor(s) for venous or arterial
                  thrombosis may also constitute a contraindication

               -  Pancreatitis or a history thereof if associated with severe hypertriglyceridemia

               -  Presence or history of severe hepatic disease as long as liver function values
                  have not returned to normal

               -  Severe renal insufficiency or acute renal failure

               -  Presence or history of liver tumours (benign or malignant)

               -  Known or suspected sex-steroid influenced malignancies (e.g. of the genital
                  organs or the breasts)

               -  Undiagnosed vaginal bleeding

               -  Known or suspected pregnancy

               -  Hypersensitivity to the active substances or to any of the excipients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 19, 2015</lastchanged_date>
  <firstreceived_date>September 21, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Premenstrual Dysphoric Disorder</keyword>
  <keyword>PMDD</keyword>
  <keyword>Acne</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
